SCHEMBL7184765

SCHEMBL7184765

CS(=O)(=O)c1[nH]c(-c2ccccc2)nc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
NPBWR1 P48145 2/20 0.46
SCD O00767 1/20 0.44
POLB P06746 2/20 0.43
MEN1 O00255 1/20 0.43
S1PR4 O95977 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
S1PR1 P21453 1/20 0.43
SDHB P21912 1/20 0.43
MAPK1 P28482 1/20 0.43
STAT3 P40763 1/20 0.43
STAT1 P42224 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TLR9 Q9NR96 1/20 0.43
PIN1 Q13526 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500317 0.79 SCD (0.54) NPBWR1SCDSMN1; SMN2ALDH1A1MAPK13
SCHEMBL9006008 0.74 HPGD (0.50) HPGDNPBWR1POLBRAB9AALDH1A1
SCHEMBL9275955 0.73 ESR1 (0.50) HPGDPOLBMEN1S1PR4LMNA
SCHEMBL655574 0.72 HPGD (0.49) HPGDNPBWR1POLBMEN1MAPK1
SCHEMBL8677012 0.71 KMT2A (0.66) HPGDNPBWR1POLBMEN1HTT
SCHEMBL25010255 0.71 LMNA (0.48) HPGDNPBWR1SCDMEN1LMNA
SCHEMBL649956 0.69 HPGD (0.45) HPGDNPBWR1MAPK1RAB9APIN1
SCHEMBL8678923 0.68 KDM4E (0.48) HPGDPOLBMEN1MAPK1HTT
SCHEMBL29286633 0.67 PIN1 (0.53) POLBRAB9AKMT2APIN1MAPK13
SCHEMBL8677247 0.67 SMN1; SMN2 (0.62) HPGDPOLBLMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1365753-A2 UROGUANYLIN AND CYCLOOXYGENASE-2 INHIBITOR COMBINATIONS FOR INHIBITION OF INTESTINAL CANCER Pharmacia Corporation (US) 2003-12-03 EP disclosed
WO-2002062369-A2 UROGUANYLIN AND CYCLOOXYGENASE-2 INHIBITOR COMBINATIONS FOR INHIBITION OF INTESTINAL CANCER PHARMACIA CORPORATION (US) 2002-08-15 WO disclosed
EP-0979077-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS G.D. Searle & Co. (US) 2000-02-16 EP disclosed
WO-1998047509-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1998-10-29 WO disclosed